GleamWall
中文EN

NYXH Nyxoah SA IFRS

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1857190 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY121.6%
TTM net income YoY-52.1%
TTM EPS YoY-30.7%
Revenue 3-yr CAGR48.1%
Net income 3-yr CAGR—

Margins

Gross margin63.1%
Operating margin-833.2%
Net margin-899.1%
FCF margin-696.4%
EBITDA margin—

Returns

ROE-111.0%
ROA-65.1%
ROIC (approx.)-134.3%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets58.5%
Debt / equity0.00x
Current ratio1.25x
Interest coverage-7.25x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-15.2%
Payout ratio—
Capex / revenue8.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q2*2025-06-302024Q22024-06-302023Q22023-06-302022Q4*2022-12-312022Q32022-09-302022Q22022-06-302021Q4*2021-12-312021Q32021-09-30
Income statement
Revenue1.34M771,0001.11M1.31M182,000936,000343,000203,000
Cost of revenue490,000281,000419,000465,00063,000334,000105,00082,000
Gross profit850,000490,000688,000842,000119,000602,000190,000121,000
R&D expense10.06M7.47M6.61M4.58M4.22M3.47M3.33M3.52M
SG&A expense10.67M6.38M6.18M5.36M4.76M4.54M3.94M4.50M
Operating income-19.85M-13.31M-11.88M-9.05M-8.78M-7.39M-6.54M-8.07M
Interest expense3.34M1.45M775,000-1.15M2.52M2.16M588,000585,000
Pretax income-20.33M-12.68M-11.87M-12.51M-6.17M-4.88M-3.53M-8.63M
Income tax278,000441,000928,000790,00065,000107,0002.72M136,000
Net income-20.61M-13.12M-12.80M-13.30M-6.24M-4.99M-6.25M-8.76M
EPS (basic)-0.55-0.43-0.45—-0.24-0.19—-0.35
EPS (diluted)-0.55-0.43-0.45—-0.24-0.19—-0.35
Balance sheet
Cash & equivalents22.73M27.72M16.60M17.89M89.88M75.60M135.51M140.91M
Receivables1.33M2.61M1.82M1.46M757,000—226,000—
Inventory5.33M5.10M1.15M882,000594,000—346,000—
Current assets55.11M89.67M91.33M100.26M119.34M—140.06M—
PP&E, netmay include right-of-use assets (IFRS)5.01M4.39M2.81M2.46M2.22M—2.02M—
Intangibles51.41M49.31M44.49M39.97M36.49M—25.32M—
Total assets116.47M148.23M142.41M146.07M164.07M—170.83M—
Current liabilities20.95M16.38M15.24M14.91M20.01M—11.57M—
Total liabilities43.07M28.09M26.84M25.75M31.00M—22.21M—
Shareholders' equity73.40M120.14M115.58M120.32M133.07M—148.62M—
Shares outstanding37.44M34.37M28.66M25.85M25.85M25.84M25.77M25.55M
Cash flow statement
Operating cash flow———-10.37M-8.66M—-7.33M—
Capital expenditure———402,000182,000—212,000—
Free cash flow———-10.77M-8.85M—-7.54M—
Investing cash flow———-58.30M20.34M—-3.34M—
Financing cash flow———-219,000-399,000—1.43M—
Stock-based compensation887,000540,000—562,000845,000—345.22M784,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.